Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma-Reference-Cited by-同舟云学术

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Published:2019-11-01 Issue: Volume: Page:clincanres.2443.2019
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kelly Ronan J.,Lee Jeeyun,Bang Yung-Jue,Almhanna Khaldoun,Blum Murphy Mariela,Catenacci Daniel V. T.,Chung Hyun Cheol,Wainberg Zev A.,Gibson Michael K,Lee Keun-Wook^ORCID,Bendell Johanna C.,Denlinger Crystal S^ORCID,Chee Cheng Ean,Omori Takeshi,Leidner Rom,Lenz Heinz-Josef,Chao Yee,Rebelatto Marlon C.,Brohawn Philip,He Peng,McDevitt Jennifer,Sheth Siddharth,Englert Judson M,Ku Geoffrey Y.^ORCID

Funder

No relevant funder

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving individualised therapies in localised gastro-oesophageal adenocarcinoma;The Lancet Oncology;2024-09

2. Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study;ESMO Open;2024-07

3. New Approaches in Gastric Cancer Immunotherapy;Gastric Cancer - Progress and Challenges in the Era of Precision Medicine [Working Title];2024-07-01

4. Immune checkpoint inhibitors in colorectal cancer: limitation and challenges;Frontiers in Immunology;2024-06-11

5. PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET;Frontiers in Immunology;2024-06-10